Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -38,327 | -37,643 | -35,531 | 241,198 |
| Depreciation and amortization | 881 | 896 | 966 | 2,062 |
| Stock-based compensation expense | 2,385 | 2,784 | 3,389 | 10,793 |
| Impairment of out-license asset and remeasurement of cvr liability, net | NaN | NaN | 1,646 | NaN |
| Write-down of intangible assets and remeasurement of contingent consideration liabilities, net | NaN | 4,164 | NaN | NaN |
| Loss on debt extinguishment | NaN | 0 | 0 | -10,286 |
| Loss on sale transactions, net (note 6) | -388 | -365 | -422 | 339,102 |
| Change in fair value of derivatives | NaN | 0 | 0 | 12,608 |
| Other non-cash adjustments, net | 468 | -4,976 | -7,842 | 2,490 |
| Trade receivables, net | 4,282 | 8,338 | 4,266 | -106,161 |
| Inventory | 11,312 | 1,114 | -2,480 | 18,474 |
| Prepaid manufacturing | -4,485 | -1,290 | 1,348 | -396 |
| Other prepaid, current and non-current assets | 3,071 | -2,367 | -3,274 | 869 |
| Accounts payable | 2,564 | -5,088 | -15,301 | 833 |
| Accrued rebates, fees and reserves | -1,631 | -30,213 | -21,061 | -68,053 |
| Tsa related operating assets and liabilities, net | 3,303 | -51,805 | -23,188 | 10,547 |
| Accrued compensation | 33 | 1,194 | 2,370 | -7,329 |
| Accrued and other current and non-current liabilities | -7,164 | 4,437 | 1,275 | -14,911 |
| Net cash used in operating activities | -57,886 | -19,716 | -46,339 | -72,458 |
| Purchases of investments in marketable securities | 6,388 | 14,262 | 68,850 | 20,726 |
| Proceeds from maturities of investments in marketable securities | 38,135 | 19,812 | 1,650 | NaN |
| Net cash received related to the sale transactions (note 6) | NaN | 8,376 | 0 | -478,681 |
| Milestone payments to junshi biosciences | NaN | 0 | 0 | 12,500 |
| Other investing activities, net | 1,092 | 12 | 27 | 303 |
| Net cash provided by (used in) investing activities | 30,655 | -2,838 | -67,227 | 445,152 |
| Proceeds from (repayment of) revenue purchase and sale agreement, net of issuance costs | NaN | 0 | 0 | -47,652 |
| Redemption of 2026 convertible notes, including transaction costs | NaN | 0 | 0 | 233,185 |
| Proceeds from issuance of common stock under private placement, net of issuance costs | NaN | 7,894 | NaN | NaN |
| Proceeds from purchase under the employee stock purchase plan | NaN | 165 | 0 | 188 |
| Proceeds from issuance of common stock under public offering, net of issuance costs | 53,650 | NaN | NaN | NaN |
| Taxes paid related to net share settlement | 112 | 0 | 3 | 280 |
| Other financing activities, net | 52 | 22 | 5 | -859 |
| Net cash provided by (used in) financing activities | 53,590 | 8,081 | 2 | -281,788 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 26,359 | -14,473 | -113,564 | 90,906 |
| Cash, cash equivalents and restricted cash at beginning of period | 89,119 | 103,592 | 126,250 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 115,478 | 89,119 | 103,592 | NaN |